"10.1371_journal.pone.0098062","plos one","2014-06-02T00:00:00Z","Benjamin Rolland; François Paille; Benoit Fleury; Olivier Cottencin; Amine Benyamina; Henri-Jean Aubin","Société Française d’Alcoologie, Issy-les-Moulineaux, France; Service d’Addictologie, CHU Lille, Univ Lille Nord de France, Lille, France; Service d’Addictologie, CHU Nancy, Université, Univ Nancy, Nancy, France; Service d'Hépatogastroentérologie et d'Alcoologie, CHU Bordeaux, Bordeaux, France; CERTA L’Albatros, Hôpital Paul Brousse, AP-HP, INSERM U 669, Villejuif, France","Conceived and designed the experiments: BR FP BF HJA. Analyzed the data: BR FP HJA. Wrote the paper: BR FP BF OC AB HJA.","Dr ROLLAND is the main investigator in a clinical trial funded by ETHYPHARM, which is developing a labelled form of baclofen for alcohol use disorders. Dr PAILLE has received sponsorship to attend scientific meetings, speaker honoraria, and consultancy fees from Lundbeck, Ethypharm, D&A Pharma, and Merck-Serono. Dr FLEURY has received sponsorship to attend scientific meetings from Lundbeck. Dr COTTENCIN is an associate Investigator in the ALPADIR clinical trial, comparing HDB vs. placebo for abstinence maintenance, which is funded by ETHYPHARM. He has received sponsorship to attend scientific meetings from Lundbeck, BMS Otsuka, Janssen Cilag, Reckitt Benckiser, Pfizer, Bouchara Recordati. Dr BENYAMINA has received sponsorship to attend scientific meetings, speaker honoraria, and consultancy fees from Merck-Serono, BMS, Reckitt-Benckiser Pharma, and Otsuka. Dr Benyamina is a member of the Lundbeck scientific board in France for Selincro. Dr AUBIN has received sponsorship to attend scientific meetings, speaker honoraria, and consultancy fees from Bioprojet, D&A Pharma, Ethypharm, Lundbeck, Merck-Serono, Novartis, and Pfizer.",NA,NA,NA,"2014","06","Benjamin Rolland","BR",6,TRUE,4,NA,3,6,TRUE,TRUE,FALSE,0,NA,FALSE
